Related Experiment Videos
Viral dynamics in hepatitis B virus infection
M A Nowak1, S Bonhoeffer, A M Hill
1Department of Zoology, University of Oxford, United Kingdom;
Summary
Lamivudine treatment rapidly reduces hepatitis B virus (HBV) in patients, clearing plasma virus in about a day. Infected cell turnover varies widely, offering insights into chronic HBV dynamics and treatment strategies.
Area of Science:
- Virology
- Hepatology
- Pharmacokinetics
Background:
- Chronic hepatitis B virus (HBV) infection is a global health concern.
- Lamivudine is a reverse transcriptase inhibitor used to treat HBV.
- Understanding HBV replication kinetics is crucial for effective treatment.
Purpose of the Study:
- To quantify HBV replication dynamics in vivo during lamivudine treatment.
- To estimate the half-life of plasma HBV particles and infected cells.
- To compare HBV dynamics with human immunodeficiency virus (HIV) infection.
Main Methods:
- Analysis of plasma viremia decline during lamivudine therapy.
- Estimation of viral release and infected cell turnover rates.
- Comparison of kinetic parameters between HBV and HIV infection models.
Main Results:
- HBV particles cleared from plasma with a half-life of approximately 1.0 day.
- Daily turnover of free virus population is approximately 50%.
- Half-lives of HBV-producing cells range from 10 to 100 days, varying by patient.
Conclusions:
- Lamivudine treatment provides quantitative insights into HBV replication kinetics.
- Infected cell turnover rates vary, potentially influenced by immune responses.
- HBV replication is quantitatively distinct from HIV, with implications for therapy timing and drug resistance.